Developed simvastatin chitosan nanoparticles co-crosslinked with tripolyphosphate and chondroitin sulfate for ASGPR-mediated targeted HCC delivery with enhanced oral bioavailability

• Päätekijät: Tarek M. Faris (Tekijä), Gamaleldin I. Harisa (Tekijä), Fars K. Alanazi (Tekijä), Ahmed M. Samy (Tekijä), Fahd A. Nasr (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Elsevier, 2020-12-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Simvastatin (SV) repurposing has emerged as an alternative approach for the treatment of cancer. In this study, SV chitosan nanoparticles co-crosslinked with tripolyphosphate and chondroitin sulfate (SVCSChSNPs) were developed in order to maximize SV therapeutic efficiency. The hepatic targeting was...